LAX.SH
WOCKHARDT LIMITED·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
1,886.3
+3.04%52W Range
Market Cap
₹30,650.90 Cr
Traded: ₹105.06 Cr (0.34%) 0.0x
Free Float: ₹10,019.78 Cr (1.05% of FF traded)
Volume · 60D trend
5.59 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -2.0% | -3.0% | -1.0% | -- | -- | Stable |
| Return | +10.0% | +34.0% | +97.0% | +31.0% | -- | Stable |
| Profit | +1.0% | -19.0% | +43.0% | -- | +983.0% | Accelerating |
| Sales | -3.0% | +4.0% | +8.0% | -- | +18.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 929 | 965 | 888 | 782 | 738 | 743 | 721 | 809 | 739 | 700 | 701 | 753 | 644 | 678 | 699 | 679 |
| Expenses | 737 | 740 | 711 | 604 | 666 | 679 | 593 | 699 | 648 | 759 | 664 | 681 | 628 | 675 | 654 | 636 |
| Operating Profit | 192 | 225 | 177 | 178 | 72 | 64 | 128 | 110 | 91 | -59 | 37 | 72 | 16 | 3 | 45 | 43 |
| OPM % | 21.0% | 23.0% | 20.0% | 23.0% | 10.0% | 9.0% | 18.0% | 14.0% | 12.0% | -8.0% | 5.0% | 10.0% | 2.5% | 0.0% | 6.0% | 6.0% |
| Other Income | 31 | 67 | 15 | 21 | -77 | 15 | 8 | 9 | 30 | 10 | 8 | 24 | 0 | -64 | -1 | -138 |
| Interest | 52 | 50 | 60 | 55 | 48 | 48 | 60 | 73 | 73 | 73 | 77 | 76 | 79 | 76 | 83 | 70 |
| Depreciation | 55 | 53 | 65 | 53 | 56 | 53 | 55 | 55 | 54 | 58 | 55 | 55 | 55 | 56 | 66 | 65 |
| Profit Before Tax | 116 | 189 | 67 | 91 | -109 | -22 | 21 | -9 | -6 | -180 | -87 | -35 | -118 | -193 | -105 | -230 |
| Tax % | 8.0% | 13.0% | 9.0% | 10.0% | -1.0% | 105.0% | 5.0% | 78.0% | 167.0% | -2.0% | -1.0% | 109.0% | 15.0% | 23.0% | -3.0% | -10.0% |
| Net Profit | 107 | 164 | 61 | 82 | -108 | -45 | 20 | -16 | -16 | -177 | -86 | -73 | -136 | -237 | -102 | -207 |
| Exceptional Items | -- | 22 | -10 | 0 | -97 | 0 | 0 | 0 | 0 | -44 | 0 | 0 | -14 | -96 | -3 | -195 |
| EPS (Rs) | 6.5 | 10.2 | 3.6 | 4.8 | -5.5 | -1.5 | 0.9 | -1.4 | -0.9 | -11.0 | -5.8 | -5.3 | -9.3 | -14.4 | -6.7 | -13.1 |
| Sales Growth (YoY) | 25.9% | 29.9% | 23.2% | -3.3% | -0.1% | 6.1% | 2.9% | 7.4% | 14.8% | 3.2% | 0.3% | 10.9% | 8.2% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 8.7% | 13.6% | 6.0% | -0.7% | 3.0% | -10.9% | 9.5% | 5.6% | -0.1% | -6.9% | 16.9% | -5.0% | -3.0% | 3.0% | -- |
| OP Growth (YoY) | 166.7% | 251.6% | 38.3% | 61.8% | -20.9% | 208.5% | 245.9% | 52.8% | 468.8% | -2066.7% | -17.8% | 67.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | -14.7% | 27.1% | -0.6% | 147.2% | 12.5% | -50.0% | 16.4% | 20.9% | 254.2% | -259.5% | -48.6% | 350.0% | 433.3% | -93.3% | 4.7% | -- |
| Profit Growth (YoY) | -- | 688.0% | 384.0% | 455.0% | 13.0% | 80.0% | 117.0% | 71.0% | 89.0% | 11.0% | 11.0% | -448.0% | -83.0% | -34.0% | -1232.0% | -141.0% |
| EPS Growth (YoY) | -- | 763.6% | 322.1% | 435.7% | -508.8% | 86.0% | 114.9% | 73.2% | 90.2% | 23.7% | 13.5% | 59.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 181.5% | -24.4% | 186.6% | -259.7% | -279.1% | 160.1% | -57.1% | 91.7% | -91.3% | -7.9% | 42.6% | 35.6% | -116.8% | 49.2% | -- |
| OP Margin | -- | 23.3% | 19.9% | 22.8% | 9.8% | 8.6% | 17.8% | 13.6% | 12.3% | -8.4% | 5.3% | 9.6% | 2.5% | 0.4% | 6.4% | 6.3% |
| Net Margin | -- | 17.0% | 6.9% | 10.5% | -14.6% | -6.1% | 2.8% | -2.0% | -2.2% | -25.3% | -12.3% | -9.7% | -21.1% | -35.0% | -14.6% | -30.5% |
| Material Cost % | -- | 33.0% | 35.7% | 29.8% | 35.8% | 35.0% | 36.3% | 36.7% | 42.4% | 42.0% | 43.1% | 38.1% | 43.8% | 45.1% | 45.8% | 38.0% |
| Employee Cost % | -- | 19.4% | 20.4% | 23.8% | 23.2% | 22.3% | 22.8% | 19.9% | 21.6% | 22.4% | 21.7% | 22.1% | 23.9% | 21.2% | 21.5% | 24.0% |
| P/S | 8.60 | 9.30 | 7.20 | 7.42 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 74.94 | 147.31 | 1033.78 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.20 | 6.35 | 4.97 | 4.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed herewith Scrutinizer''s Report on the combined voting results of remote e-voting and e-voting during the 27th AGM of the Company
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, the Proceedings of the 27th AGM of the Company
Pursuant to Regulation 32(6) of SEBI (LODR) Regulations 2015, read with Regulation 173A of SEBI (ICDR) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilisation ....
Please find enclosed Press Release - "Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug Resistance".
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026
Pursuant to Regulation 30 of SEBI Listing Regulations, the Board of Directors at its meeting held today i.e. 10th August, 2026, has approved the Unaudited Financial Results (Standalone ....
Pursuant to Regulation 30 of SEBI Listing Regulations, Board of Directors at its meeting held today i.e 10th August, 2026 has approved the Unaudited Financial Results (Standalone and Consolidated) ....
Pursuant to Regulation 30 read with schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find ....
Please find enclosed herewith the addendum to the Notice of the 27th Annual General Meeting of the Company scheduled to be held on Monday, 10th August, 2026.
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....
Please find enclosed the copies of Newspaper Advertisement published today i.e. 18th July, 2026 in respect to the information regarding the 27th Annual General Meeting (''AGM'') of the ....
Please find enclosed the Business Responsibility and Sustainability Report and Independent Assurance Statement on BRSR Core parameters issued by SGS India Private Limited for the Financial ....
Please find enclosed herewith the Notice of 27th Annual General Meeting of Wockhardt Limited scheduled to be held on Monday, 10th August, 2026, at 3:30 p.m. through Video Conferencing/ ....
Please find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26.
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Registrar and ....
Pursuant to Regulation 30 read with Schedule III (Part A Para A) of SEBI Listing Regulations, please find enclosed herewith newspaper extracts of public notice relating to 27th AGM of the ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith newspaper advertisement published today i.e. 26th June, ....
This is to inform that pursuant to Company''s ''Code of Conduct for regulating, monitoring and reporting of trading by designated persons'' (''the Code''), the Trading Window for dealing ....
Pursuant to Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref.no. WOCK/SEC/SE/2025-26/015 ....
Pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015, we wish to inform you that the Company will hold an Investor Meet on Thursday, 4th June, 2026 at 4:00 pm IST.
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam), a Novel Intravenous Antibiotic ....
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Secretarial Compliance Report for the year ended 31st March, 2026
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Indian drug regulator grants marketing authorization to Wockhardt''s breakthrough antibiotic , ZAYNICH ....
ICRA Limited has upgraded the Credit Rating as given below: Long Term- Fund Based- Term Loan- Present Rating- A- (Stable); Previous Rating- BBB (Positive) Long Term/ Short Term- Fund ....
Monitoring Agency Report for quarter ended 31st March, 2026.
Change in Senior Management Personnel.
please find enclosed herewith Audited Financial results for the quarter and financial year ended 31st March, 2026.
Submission pursuant to Regulation 30 (LODR)Regulations, 2015- Press Release
Please be informed that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, inter-alia, has approved: i. the Audited Financial Results and Financial Statements ....
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 ,inter alia, to consider and approve We wish to inform you that a meeting ....
News paper advertisement under Regulation 30 read with Schedule III part A para A of SEBI Listing Regulations regarding opening of special window for re-lodgment of transfer requests of ....
Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release- "Wockhardt''s Zaynich (Zidebactam/ Cefepime) Receives Favourable Recommendation from CDSCO''s Subject ....
This is to inform you that pursuant to Company''s ''Code of Conduct for Regulating, Monitoring and Reporting trading by Designated Persons'', the Trading Window for dealing in equity shares ....
Pursuant to Regulation 30 read with Schedule III Part A Para A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, ....
Monitoring Agency Report for the quarter ended December 31, 2025.
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and nine months ....
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015; and in continuation to our letter bearing reference no: WOCK/SEC/SE/2025-26/065 dated 4th February, 2026, we wish to inform you ....
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); and in continuation to ....
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....
In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ....
Pursuant to Regulation 30 0f Listing Regulations, please find enclosed Press Release- "Wockhardt''s Fifth Novel Antibiotic, Foviscu (WCK 4282), Matches Gold Standard Meropenem in pivotal ....
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that CFC Finlease ....
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Registrar and ....
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release- "Wockhardt Files Marketing Authorisation Application for WCK 5222 with European Medicines Agency".
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby inform you that ESG Risk Assessments & Insights Limited, a SEBI registered ....
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby inform you that SES ESG Research Pvt ltd has voluntarily assigned an ....
In terms of provision of Regulation 30 (read with Part A of Schedule lll) and other applicable provisions of the SEBI (LODR)Regulations, 2015, we wish to inform you that the Company is ....
Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "European Medicines Agency Grants Accelerated Assessment to WCK 5222".
Annual Reports
16Credit Ratings
6Concalls
7Jun 2025
30 Jun 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Oct 2024
31 Oct 2024Feb 2024
29 Feb 2024Feb 2023
28 Feb 2023Mar 2022
31 Mar 2022Held by ETFs
15 ETFs hold WOCKPHARMA · sorted by weight
Held by Mutual Funds
57 schemes hold WOCKPHARMA · sorted by weight